|
|
Article: MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes.
- Article from:
- PR Newswire
- Article date:
- September 16, 2008
CopyrightCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Study 009 meets its primary endpoint of non-inferiority to a rapid-acting insulin analog
VALENCIA, Calif., Sept. 16 /PRNewswire-FirstCall/ -- MannKind Corporation today released preliminary top-line results from a Phase 3 clinical study of the Technosphere(R) Insulin System in patients with type 1 diabetes (Study 009). This study compared the safety and efficacy of prandial inhalations of Technosphere Insulin (the TI group) versus prandial subcutaneous injections of insulin aspart (the comparator group). Both groups also received daily subcutaneous injections of a basal insulin (insulin glargine).
Study Highlights
Technosphere Insulin, compared ...